

PR 14-MAY-1999; 990S-0311940.
XX (INCY-) INCYTE GENOMICS INC.
XX Yue H, Tang YT, Lal P, Reddy R, Batra S, Baughn MR, Yang J;
PI Azimzal Y, Lu DM, Au-Young J, Shih LL,
XX WPI: 2001-016234/02.
DR P-PSDB: AAB36609.
XX
PT Human FLEXHT protein and DNA sequences, useful for treating
PS immunological disorders, developmental disorders, and cancers -
XX
PS Claim 5; Page 154; 168pp: English.
XX
XX AAC8070 to AAC88124 encode the 55 FLEXHT (full-length molecules
CC expressed in human tissues) proteins given in AAB3579 to AAB36633. The
CC present invention describes an isolated polypeptide (A) comprising an
CC amino acid sequence selected from one of 55 amino acid sequences 42-876
CC residues in length, corresponding to FLEXHT-1 to FLEXHT-55, a 90 %
CC identical sequence, and a biologically active or immunogenic fragment of
CC the sequence. The FLEXHT proteins can have antianemic, anticonvulsant,
CC antiarteriosclerotic, immunomodulatory, cytostatic, antidiabetic,
CC antiinflammatory, hepatotropic, antidiabetic, anti-gout, antithyroid,
CC neuroprotective, antiarthritic, osteopathic, antipsoriatic, antitumor
CC and antineumatic activities, and can be used in gene therapy. The
CC polynucleotide sequences can be used to express the protein sequences.
CC Pharmaceutical compositions comprising FLEXHT can be used to treat
CC diseases or conditions associated with altered expression of functional
CC FLEXHT. The proteins and polynucleotides can be used to diagnose and
CC treat disorders including anaemia, epilepsy, arteriosclerosis,
CC atherosclerosis, developmental disorders, cancers, and immunological
CC disorders such as asthma, bronchitis, cirrhosis, Crohn's disease,
CC diabetes mellitus, gout, Grave's disease, multiple sclerosis,
CC osteoarthritis, pancreatitis, psoriasis, rheumatoid arthritis, and
CC ulcerative colitis.
XX
SQ Sequence 1071 BP: 338 A; 190 C; 297 G; 246 T; 0 other;

Query Match 100.0%; Score 873; DB 22; Length 1071;
Best Local Similarity 100.0%; Pred. No. 3,66-231;
Matches 873; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 tggagtgagggtaacaagatggcgagcggtggaagctccataaagcttgc 60
DB 165 tggagtgagggtaacaagatggcgagcggtggaagctccataaagcttgc 224
QY 61 cgaactaaagcaagatgcttgcgtggtttggaagcaggaggaataaagaatct 120
DB 225 cgaactaaagcaagatgcttgcgtggtttggaagcaggaggaataaagaatct 284
QY 121 tatccacagatccagagcatcttgaagaacatgctgagaaggaagcaatgaaga 180
DB 285 tatccacagatccagagcatcttgaagaacatgctgagaaggaagcaatgaaga 344
QY 181 tgtactggagatgaacagaggaagaacaaagccattgagctccctgtcaaga 240
DB 345 tgtactggagatgaacagaggaagaacaaagccattgagctccctgtcaaga 404
QY 241 ggaagaacccctgtgaataacgtgtgagtggcagcagaagaagaagtgtaaat 300
DB 405 ggaagaacccctgtgaataacgtgtgagtggcagcagaagaagaagtgtaaat 464
QY 301 atctgaataacacagactgagagaatgtagagaagggctgacgaatcaatgtact 360
DB 465 atctgaataacacagactgagagaatgtagagaagggctgacgaatcaatgtact 524
QY 361 gagcttgagagtaagaagagctgctcgagcactaaggtttggaattcttcagtt 420
DB 525 gagcttgagagtaagaagagctgctcgagcactaaggtttggaattcttcagtt 584
QY 421 aaaaggtctgcatctgataacaacctaagttaacttgatgaagctgaaggaagagc 480

DB 585 aaaaggtctgcatctgataacaacctaagttaacttgatgaagctgaaggaagagc 644
QY 481 tcaagatttgattgaatgctctccaatcccaagaagctgaagatgagagaact 540
DB 645 tcaagatttgattgaatgctctccaatcccaagaagctgaagatgagagaact 704
QY 541 gaaaaagaggaagagcagatttggatgtgcaaaatcagctggaactggaaccacaga 600
DB 705 gaaaaagaggaagagcagatttggatgtgcaaaatcagctggaactggaaccacaga 764
QY 601 ggatacagagcagaagaagaagaagacagagcgtttggatgtgctgtatgaagt 660
DB 765 ggatacagagcagaagaagaagaagacagagcgtttggatgtgctgtatgaagt 824
QY 661 tctgtactcttctgtcccaagtggttcccaatctccctctctctgtgatacata 720
DB 825 tctgtactcttctgtcccaagtggttcccaatctccctctctctgtgatacata 884
QY 721 tgcctaaatgacacagtcagtcctcagtcctcagcaatgaggaagcatgtaccaca 780
DB 885 tgcctaaatgacacagtcagtcctcagtcctcagcaatgaggaagcatgtaccaca 944
QY 781 ggtacatcatgaacacgagcagcagattgactatctgttcaagcttaagttgt 840
DB 945 ggtacatcatgaacacgagcagcagattgactatctgttcaagcttaagttgt 1004
QY 841 ggtatttggatttggatttggatttggatttggatttggatttggatttggattt 873
DB 1005 ggtatttggatttggatttggatttggatttggatttggatttggatttggattt 1037
RESULT 2
AAS29109
ID AAS29109 standard; cDNA; 1154 BP.
XX
AC AAS29109;
XX
DT 21-NOV-2001 (first entry)
XX
DE cDNA encoding for human DNA-binding protein #80.
XX
XX
KW Human; DNA-binding protein; histone; chromo domain protein;
KW chromatin organisation modifier; Y-box binding protein;
KW DNA Organisation; gene transcription; malignant disease;
KW autoimmune disorder; rheumatic disease; genetic abnormality;
KW infectious disease; neurological disorder; gene therapy;
KW immunomodulatory; anti-HIV; anti rheumatic; anti microbial;
KW cytosolic; ss.
OS Homo sapiens.
PN WO20015162-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01305.
XX
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.

PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 23-AUG-2000; 2000US-0227182.
PR 30-AUG-2000; 2000US-0227009.
PR 01-SEP-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.

PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250161.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.

(HUMA-) HUMAN GENOME SCI INC.
Rosen CA, Barash SC, Ruben SM;
WPI; 2001-465557/50.
P-PSDB; AAU18233.

Nucleic acid molecules encoding human secreted chromosomal binding proteins, used in preventing, treating or ameliorating a disorder, e.g. Alzheimer's and Parkinson's diseases and cancers -
Claim 4; SEQ ID No 90; 561bp; English.

The present invention relates to the isolation of novel DNA-binding proteins (AAU18154-AAU18281), and cDNA and genomic sequences encoding for these proteins. DNA-binding proteins such as histones, chromo (chromatin organisation modifier) domain proteins, and Y-box binding proteins may contribute to diseases resulting from aberrant DNA organisation and/or gene transcription. The sequences of the invention are useful in screening assays to identify antagonists and/or agonists that may enhance or block activities mediated by DNA-binding proteins. Blockers of DNA-binding proteins may be useful in treating disorders such as malignant diseases (e.g. cancer), autoimmune disorders (e.g. diabetes mellitus), rheumatic diseases (e.g. rheumatoid

CC arthritis), genetic abnormalities (e.g. cystic fibrosis), infectious
CC diseases (e.g. HIV) and neurological disorders (e.g. Alzheimer's
CC disease). The polynucleotide sequences of the invention may also be
CC used in gene therapy. AAS29030-AAS29157 represent cDNA sequences
CC encoding for novel DNA-binding proteins.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPo
CC at [ftp.wipo.int/pub/published_pct_sequences](http://wipo.int/pub/published_pct_sequences).

XX Sequence 1154 BP; 394 A; 186 C; 291 G; 281 T; 2 other;

Query Match 100.0%; Score 873; DB 22; Length 1154;
Best Local Similarity 100.0%; Pred. No. 3,7e-231;
Matches 873; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY 1 tggagtggagggttaacaagatgagccgagagcgttgagccatcaagtaagcttgc 60
DB 182 tggagtggagggttaacaagatgagccgagagcgttgagccatcaagcttgc 241
OY 61 cgaactaaagcaagaatgctctgctcgctgcttgagacaaaggaggaataaagaatct 120
DB 242 cgaactaaagcaagaatgctctgctcgctgcttgagacaaaggaggaataaagaatct 301
OY 121 tatccacagactccagcgcatactctgaagaacatgctgaaggaggaacatgaagaaga 180
DB 302 tatccacagactccagcgcatactctgaagaacatgctgaaggaggaacatgaagaaga 361
OY 181 tctactggagatgtaaacagagaagaagaagaagccatctgagctccctgtcaaga 240
DB 362 tctactggagatgtaaacagagaagaagaagaagccatctgagctccctgtcaaga 421
OY 241 ggaagaacccccctgaaaaaactgttgatgctgagcagcagaagaagaagtgtgtaaatlac 300
DB 422 ggaagaacccccctgaaaaaactgttgatgctgagcagcagaagaagaagtgtgtaaatlac 481
OY 301 atctgaataaccacagactgtagaagaatgtagaagaaggctgtagaagatcaatgtaactct 360
DB 482 atctgaataaccacagactgtagaagaatgtagaagaaggctgtagaagatcaatgtaactct 541
OY 361 gagcttgtagagtaagaagagctgcgcgagcagctaggtttgagattcttcagctccaac 420
DB 542 gagcttgtagagtaagaagagctgcgcgagcagctaggtttgagattcttcagctccaac 601
OY 421 aaaaagctcgtcatctgtaaacaaactatggtttaacttgaataagctgtaagaagaagc 480
DB 602 aaaaagctcgtcatctgtaaacaaactatggtttaacttgaataagctgtaagaagaagc 661
OY 481 tcaaaagatttggtttggaatgctcttcaatccacagaagcttgaagaatgtagaagaact 540
DB 662 tcaaaagatttggtttggaatgctcttcaatccacagaagcttgaagaatgtagaagaact 721
OY 541 gaaaaagaggaagagcagatttggaatgctcaagaatgtagtgaactgtagaaccacaga 600
DB 722 gaaaaagaggaagagcagatttggaatgctcaagaatgtagtgaactgtagaaccacaga 781
OY 601 ggaatcagagcagaagaagaagaagaagaagcagcgtttggaatgctcgtatgtaaaagt 660
DB 782 ggaatcagagcagaagaagaagaagaagaagcagcgtttggaatgctcgtatgtaaaagt 841
OY 661 tcttgatcttctgcttccacagtgcttccatcttcctcctctctcttggtccacatata 720
DB 842 tcttgatcttctgcttccacagtgcttccatcttcctcctctctcttggtccacatata 901
OY 721 tgcctcaaatgcaagatcatgctcagctcgtcgtcgtcgaatgtaggaggaatgtagtccca 780
DB 902 tgcctcaaatgcaagatcatgctcagctcgtcgtcgtcgaatgtaggaggaatgtagtccca 961
OY 781 ggtacatcatgaaactgtagcagcagcttgaactatgctgcttccagctttaaagttgtt 840
DB 962 ggtacatcatgaaactgtagcagcagcttgaactatgctgcttccagctttaaagttgtt 1021
OY 841 ggtcttctgcttctgataatgctgcttgaat 873
```

DB 1022 ggtcttctgcttctgataatgctgcttgaat 1054

RESULT 3

AAS62602/c
ID AAS62602 standard; cDNA; 891 BP.

AC AAS62602;

DT 14-FEB-2002 (first entry)

XX cDNA sequence #389 encoding novel human secreted protein.

DE Human secreted protein; hyperproliferative disorder; autoimmune disorder;

KW immune deficiency disorder; blood disorder; inflammatory disorder;

KW infectious disorder; gene therapy; antimicrobial; hepatotropic;

KW immunosuppressive; antineumatic; ss.

OS Homo sapiens.

PN WO200177291-A2.

PD 18-OCT-2001.

PF 29-MAR-2001; 2001WO-US10485.

PR 06-APR-2000; 2000US-195604P.

PS (GENEY) GENETICS INST INC.

PI Wong GG, Clark HF, Fechtel K, Agostino MJ, Howes SH, Resnick RJ;

PT Gulkota K, Graham JR;

PS New polynucleotides encoding secreted proteins useful for treating e.g.

XX asthma, HIV and Crohn's disease -

XX Claim 1; Page 280; 391pp; English.

CC The present invention relates to the isolation of novel cDNA sequences
CC which encode human secreted proteins. The cDNA sequences have been
CC derived from a variety of human tissues. The invention also provides
CC a method for producing proteins from these polynucleotide sequences.
CC The proteins are useful for identifying compounds that modulate their
CC activity and production, and the cell is also useful for identifying
CC compounds that modulate expression of the polynucleotide sequences
CC encoding the secreted proteins. The sequences of the invention are
CC useful for treating diseases such as hyperproliferative disorders
CC (e.g. cancer), immune deficiency disorders (e.g. severe combined
CC immunodeficiency (SCID)), autoimmune disorders (e.g. multiple
CC sclerosis), blood disorders (e.g. thrombocytopenia), inflammatory
CC disorders (e.g. arthritis) and infectious disorders (e.g. hepatitis).
CC The polynucleotide sequences of the invention are also useful in gene
CC therapy. AAS62214-AAS62838 represent the cDNA sequences of the
CC invention that encode for novel human secreted proteins.

XX Sequence 891 BP; 221 A; 224 C; 157 G; 289 T; 0 other;

Query Match 97.8%; Score 853.4; DB 24; Length 891;
Best Local Similarity 99.8%; Pred. No. 8,7e-226;
Matches 865; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

OY 8 aggggttaaaaatgtagcagcagagcgtgtagctccataaagcttgcgaacta 67

DB 886 AAGGTAACAAAGATGCGCGACCGAGCGGTGAGCTCCATTAACCTTAAGCTTCCGAAACTA 827

OY 68 aagcaagaatgctctgctgctgcttggagcagaaggagataaagaactctacac 127

DB 826 AAGCAAGAAATGTCTTCTGCTGCTTTGGAGACCAAGGGAATAAAGCAAGATCTTATCCAC 767

OY	128	agaccacccggaatctcttgaagaacaatgcgtgaagaaggcgaatlgaaagaagtactctg	187
Db	766	AGACCTCAGGSCATTCCTTGAAGAACAATGCCTGAAGAAGCGCAAAATGAAGAAGATGTACTG	707
OY	188	ggaagatgaaacagaggaaagaacaacaagcccatgagccccctgccaagaggagaa	247
Db	706	GGAGTTGAAACAGAGGAAGAAGAAAACAAGGCCCATTTGAGCTCCCTGTCCAAGAGGAAGAA	647
OY	248	ccccctgaaaaaacctgttgatctgtgcagcagaagaagaagtgtgtgaaaatatcatctgaa	307
Db	646	CCCCCTGAAAAAAGCTGTTGATGTGGCAGCAGAGAAGAAAGTGCGAATAATTACATCTGAA	587
OY	308	ataccacagacttgagaagaatgcagaagaaggcgctgaacgatccaattacctgtgaacctg	367
Db	586	ATACACACGAGCTGAGAGATGCACAGAAGGGCTTAAGCATTCATGTACCTGTGAGCTTG	527
OY	368	gagagtaagaagaagctggcccggcgagcctaggttttgagatttcctaagtlccaacaaaggt	427
Db	526	GAGACTTAGAAAGCTGCTCGGGCAGCTAGGTTTGAGATTCTTCAATCCAAACAAAAGT	467
OY	428	ctgtcatctgtatacaaaacctatgtttaacttggataaagctgaagaagaagctcaaga	487
Db	466	CTGTATCTGTGATPAACAAACCCTATGTTACTGTGATTAAGCTGAAGAGAAAGCTCAAGA	407
OY	488	ttagtgttgaatlyticctctccaactccagaagatctgaagaatgatsgaacttgaanaag	547
Db	406	TTTGGTTTGAATGTCCTCTTCATCTCCAGAAAGTCTGAAGATGATGAGAAACTGAANAAG	347
OY	548	aggaagagcgatlttgagattgtcacaaagtccaagctgaac-tgaaaccaagaaggttac	606
Db	346	AGGAAGGAGCGATTTGGATTGTACACAAGTTCACGCTGGAACCTGGAACACACAGAGGATAC	287
OY	607	agaggaacaagaagagaaagaagcagaagcgcttggagatgacctgatgaanaagttcctga	666
Db	286	AGAGGCCAAGAAGAGGAAGAAAGACAGACAGCCGTTTGGGATTCCTGATGAAAAGTTCCTGA	227
OY	667	tacttctgtctccagtgyltttccattctctctctctctctcttcttcttgatcacatatgctta	726
Db	226	TACTTTCGTCTCCAGAGTGTTCATATTCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTA	167
OY	727	aatgacacgatattgtcctaagctctgctcgtcgcataagaaggagagatgtlaccacaggtaca	786
Db	166	AATGACACGPTATGTGCTTACGCTCTGCTCGCAATAGAGGAGCATGTACCCCAGGTACA	107
OY	787	lccaatgaactcgcgacagcagcttgaactattgtcgttttcaaagccttaagrttgtgtgtt	846
Db	106	TCCATGAACTCGCGCAGCAGAGTTTACATTATGTGCTGTTCACGCTTTAAGGTTGTGTGTTT	47
OY	847	tgtgttttgattatgttgtctgttaat 873	
Db	46	TTGTTTTGATTATGTGCTCTGTTAAT 20	
RESULT 4			
AAC00738			
ID	AAC00738 standard; cDNA; 471 BP.		
XX	AAC00738;		
AC	AAC00738;		
XX	06-OCT-2000 (first entry)		
DT			
XX			
DE	Human secreted protein 5' EST, SPO ID NO: 736.		
XX			
KW	Human: 5' EST; expressed sequence tag; secreted protein; cDNA isolation;		
KM	gene therapy; chromosome mapping; ss.		
OS	Homo sapiens.		
XX			
PN	EP1033401-A2.		
XX			
PD	06-SEP-2000.		
XX			
PF	21-FEB-2000; 2000EP-0200610.		

XX 26-FEB-1999; 9905-0122487.
PR
XX (GEST) GENSET.
PA
XX
PI Dunas Milne Edwards J, Duclert A, Giordano J;
DR WPI: 2000-500381/45.
XX P-PSDB: AAG00732.
XX
PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
XX diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
XX Claim 1: SEQ ID 736; 71pp + CD-ROM; English.

CC The present sequence is one of a large number of 5' ESTs derived from
CC mRNAs encoding secreted proteins. An ORF has been identified within the
CC sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
CC derived from 30 different tissues. EST sequences usually correspond
CC mainly to the 3' untranslated region (UTR) of the mRNA because they are
CC often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
CC well suited for isolating cDNA sequences derived from the 5' ends of
CC mRNAs and even in those cases where longer cDNA sequences have been
CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
CC mRNAs with intact 5' ends and can therefore be used to obtain full length
CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
CC gene therapy and chromosome mapping procedures. They are used to obtain
CC upstream regulatory sequences and to design expression and secretion
CC vectors.

SQ Sequence 471 BP; 165 A; 81 C; 130 G; 94 T; 1 other:

Query Match	Similarity	Score	465.6	DB 21	Length 471
Best Local	Similarity	99.8%	Pred. No. 15-118		
Matches	465: Conservative	1	Mismatches	0	Indels
					Gaps
					0
QY	1 tggagctgaagggttaacaagaatgctgcacccagacagctgtgagctccataaagctaaagcttcg	60			
Db	6 tggagctgaagggttaacaagaatgctgcacccagacagctgtgagctccataaagctaaagcttcg	65			
QY	61 cgaactaaagcaagaatgtctgtctgtcgtggtttggagaccaaagggaataaagcaagatct	120			
Db	66 cgaactaaagcaagaatgtctgtctgtcgtggtttggagaccaaagggaataaagcaagatct	125			
QY	121 tatccacagactccagcgcatatcttgaagaacaatctgtgaaggagagcgcaatgtgaaga	180			
Db	126 tatccacagactccagcgcatatcttgaagaacaatctgtgaaggagagcgcaatgtgaaga	185			
QY	181 tgtactggagagctgaacaagagagaagaagaacaagcccatgtagctccctgtcaaga	240			
Db	186 tgtactggagagctgaacaagagagaagaagaacaagcccatgtagctccctgtcaaga	245			
QY	241 ggaagaaccccccttgaaaaaactgttgatgtggcagcagagaagaagtgtgaaaaattac	300			
Db	246 ggaagaaccccccttgaaaaaactgttgatgtggcagcagagaagaagtgtgaaaaattac	305			
QY	301 atctgaataataccacagactgagagaatgcagagaagaggtctgaacgattcaatgltactgt	360			
Db	306 atctgaataataccacagactgagagaatgcagagaagaggtctgaacgattcaatgltactgt	365			
QY	361 gggcttggagaaataagaagctgtcttcggcgcaactagggttgggattcttcagttccaac	420			
Db	366 gggcttggagaaataagaagctgtcttcggcgcaactagggttgggattcttcagttccaac	425			
QY	421 aaaagctgtcatctgtataacaacaactgtgttaacttggataag	466			
Db	426 aaaagctgtcatctgtataacaacaactgtgttaacttggataag	471			

ID AAH81555 standard; DNA; 408 BP.
XX
XX AAH81555;
AC
XX 21-SEP-2001 (first entry)
DT
XX
DE Human differential transcription-associated cDNA SEQ ID 64.
XX
XX Differential transcription; human; rat; tumour cell; cytostatic;
KW Ras modulator; Class II tumour suppressor gene; gene therapy; ss.
XX
OS Homo sapiens.
XX
XX WO200157058-A2.
PN
XX
XX 09-AUG-2001.
PD
XX
XX 31-JAN-2001; 2001WO-EP01003.
PF
XX
XX 31-JAN-2000; 2000DE-1004102.
PR
XX
XX (META-) METAGEN GES GENOMFORSCHUNG MBH.
PA
XX
PI Rosenthal A, Hinzmann B, Schaefer R, Zuber J, Tehermitza O;
PI Grips M, Hellriegel M, Schmitz A, Sers C;
XX
XX WPI; 2001-483415/52.
DR
XX
XX Nucleic acids differentially expressed between tumor and normal cells,
PT useful for diagnosis or therapy of tumors and for screening active
PT agents -
XX
XX
XX Disclosure; Page 350; 579pp; German.
XX
XX
CC This invention describes a nucleic acid (I) with differential expression
CC between tumour and normal cells and which has cytostatic activity. (I)
CC work as modulators of Ras activity by inducing expression of tumour
CC suppressor genes. (I), and polypeptides encoded by them, are useful as
CC targets for diagnosis or therapy and in screening to determine the
CC effects of an active compound (potential pharmaceutical) on a cell line,
CC particularly for diagnosis and treatment of tumors, especially by
CC modulating expression of (I) (by gene therapy, antisense RNA or ribozyme
CC methods) or by modulating the amount and/or location of (I)-encoded
CC polypeptides (by administration of the polypeptide or its activator,
CC antibody (optionally as a conjugate) or inhibitor). The method allows
CC identification of many Class II tumour suppressor genes (i.e. genes that
CC are not primary targets for tumour-initiating mutations).
CC AAH81492-AAH82376 represent the human and rat derived nucleic acid
CC fragments described in the method of the invention.
XX
XX
SQ Sequence 408 BP; 141 A; 66 C; 111 G; 88 T; 2 other;

Query Match 38.3%; Score 334; DB 22; Length 408;
Best Local Similarity 98.0%; Pred. No. 2,2e-82;
Matches 400; Conservative 0; Mismatches 2; Indels 6; Gaps 6;

QY 185 ctggagatgaatacagagagaagaacaaagccattgagctcccttcaagaaggaa 244
DB 1 ctggagatgaatacagagagaagaagaacaaagccattgagctcccttcaagaaggaa 60
QY 245 gaacccctgaaaaaactgtgatgtgacagagagaagaagtggtgaaaaattacatc 304
DB 61 gaacccctgaaaaaactgtgatgtgacagagagaagaagtggtgaaaaattacatc 120
QY 305 gaatacacacagactgagagaatgacagaagagctgaacgattcaatgtacctgtgac 364
DB 121 gaatacacacagactgagagaatgacagaagagctgaacgattcaatgtacctgtgac 180
QY 365 ttggagagtaaaaaagctctgcggcagctaaagtgtgattcttcaatccaaacaaa 424
DB 181 ttggagagtaaaaaagctctgcggcagctaaagtgtgattcttcaatccaaacaaa 240

QY 425 ggtctgcatctgatacaacaacctatggttaactt-ggataagctgaaggaaagact-c 482
DB 241 ggtctgcatctgatacaacaacctatggttaacttggataagctgaaggaaagactcc 300
QY 483 aagatttggttgaatgctcttcaatctccagaagctc-tgaagatgatga-gaaact 540
DB 301 aagatttggttgaatgctcttcaatctccagaagctc-tgaagatgatga-gaaact 360
QY 541 gaaaaaga-ggaagagagactt-ggattgtcacagactcagctgga 586
DB 361 gaaaaagaaggaagagagacttggagattgtcacagactcagctgga 408

RESULT 6
AAL37635/C
ID AAL37635 standard; DNA; 5469 BP.
XX
XX AAL37635;
AC
XX
XX 08-JAN-2002 (first entry)
DT
XX
XX
DE Human musculoskeletal system related polynucleotide SEQ ID NO 4000.
XX
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein;
KW musculoskeletal system; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200155367-A1.
PN
XX
XX 02-AUG-2001.
PD
XX
XX 17-JAN-2001; 2001WO-US01338.
PF
XX
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226281.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227099.

PR	30-ANG-2000	2000US-0228924
PR	01-SEP-2000	2000US-0229287
PR	01-SEP-2000	2000US-0229243
PR	01-SEP-2000	2000US-0229344
PR	01-SEP-2000	2000US-0229345
PR	05-SEP-2000	2000US-0229509
PR	05-SEP-2000	2000US-0229513
PR	06-SEP-2000	2000US-0230437
PR	06-SEP-2000	2000US-0230438
PR	08-SEP-2000	2000US-0231442
PR	08-SEP-2000	2000US-0231443
PR	08-SEP-2000	2000US-0231444
PR	08-SEP-2000	2000US-0231413
PR	08-SEP-2000	2000US-0231414
PR	08-SEP-2000	2000US-0232080
PR	08-SEP-2000	2000US-0232081
PR	12-SEP-2000	2000US-0231968
PR	14-SEP-2000	2000US-0232997
PR	14-SEP-2000	2000US-0232398
PR	14-SEP-2000	2000US-0232399
PR	14-SEP-2000	2000US-0232401
PR	14-SEP-2000	2000US-0232401
PR	14-SEP-2000	2000US-0233063
PR	14-SEP-2000	2000US-0233064
PR	14-SEP-2000	2000US-0233065
PR	21-SEP-2000	2000US-0234422
PR	21-SEP-2000	2000US-0234423
PR	25-SEP-2000	2000US-0234997
PR	25-SEP-2000	2000US-0234998
PR	26-SEP-2000	2000US-0235484
PR	27-SEP-2000	2000US-0235834
PR	27-SEP-2000	2000US-0235836
PR	29-SEP-2000	2000US-0236527
PR	29-SEP-2000	2000US-0236527
PR	29-SEP-2000	2000US-0236368
PR	29-SEP-2000	2000US-0236369
PR	29-SEP-2000	2000US-0236370
PR	02-OCT-2000	2000US-0237037
PR	02-OCT-2000	2000US-0237038
PR	02-OCT-2000	2000US-0237039
PR	02-OCT-2000	2000US-0237040
PR	13-OCT-2000	2000US-0239935
PR	13-OCT-2000	2000US-0239937
PR	20-OCT-2000	2000US-0240960
PR	20-OCT-2000	2000US-0241121
PR	20-OCT-2000	2000US-0241185
PR	20-OCT-2000	2000US-0241787
PR	20-OCT-2000	2000US-0241786
PR	20-OCT-2000	2000US-0241809
PR	20-OCT-2000	2000US-0241826
PR	01-NOV-2000	2000US-0246417
PR	08-NOV-2000	2000US-0246475
PR	08-NOV-2000	2000US-0246476
PR	08-NOV-2000	2000US-0246477
PR	08-NOV-2000	2000US-0246478
PR	08-NOV-2000	2000US-0246523
PR	08-NOV-2000	2000US-0246524
PR	08-NOV-2000	2000US-0246525
PR	08-NOV-2000	2000US-0246526
PR	08-NOV-2000	2000US-0246527
PR	08-NOV-2000	2000US-0246528
PR	08-NOV-2000	2000US-0246639
PR	08-NOV-2000	2000US-0246652
PR	08-NOV-2000	2000US-0246651
PR	08-NOV-2000	2000US-0246611
PR	17-NOV-2000	2000US-0246613
PR	17-NOV-2000	2000US-0249207
PR	17-NOV-2000	2000US-0249208
PR	17-NOV-2000	2000US-0249209
PR	17-NOV-2000	2000US-0249210

PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249287.
 PR 17-NOV-2000; 2000US-0249289.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0259678.
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Barash SC, Ruben SM;
 DR WPI; 2001-451937/48.
 XX
 PT Isolated polypeptide for treating, preventing and/or prognosing
 PT disorders related to the musculoskeletal system including
 PT musculoskeletal cancers and also for testing and detection e.g.
 PT diagnosis -
 PS
 XX
 XX Example 2: SEQ ID NO 4000; 761pp + Sequence Listing; English.
 XX
 CC The invention relates to novel genes (AAL34669-AAL37666) and proteins
 CC (AAB03087-AAB04109) associated with the musculoskeletal system useful
 CC for preventing, treating or ameliorating medical conditions e.g. by
 CC protein or gene therapy. The genes are isolated from a range of human
 CC tissues disclosed in the specification. The nucleic acids, proteins,
 CC antibodies and (antagonists are useful in the diagnosis, treatment
 CC and prevention of: (a) cancer, e.g. breast and ovarian cancer and
 CC other cancers of the adrenal gland, bone, bone marrow, breast,
 CC gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
 CC (c) cardiovascular disorders such as myocardial ischaemia; (d) wound
 CC healing; (e) neurological diseases e.g. cerebral anoxia and epilepsy;
 CC and (f) infectious diseases such as viral, bacterial, fungal and
 CC parasitic infections.
 CC Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 5469 BP; 1793 A; 1119 C; 1201 G; 1356 T; 0 other;

Query Match	30.4%;	Score 265.4;	DB 22;	Length 5469;
Best Local Similarity	99.6%;	Pred. No. 6.5e-63;		
Matches 266;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;

Oy 607 agagtcacaaagaagaggaaaaagcagcgctttggatltgcttga tgaanaagtlcttcta 666
| | | | |
Db 4965 ACAGGCAAGAAGAGGAAAAAGCAGACGCCCTTTGGGATTCCTGTGAATAAAAGTTCCTGA 4906

Qy 667 lacticlgtlctcagltgttccatltctctctcttcttctgttgcacatalagccta 726
|||||
Db 4905 TACTTCTGTCTCCAGTGTTCATTTCTCTCTTCTTGTCACATATATGCCGA 4846
Qy 727 aatgcacagtcattgtgcctagtcctgcctgcacatgagagagcatgtacccccagtlaca 786
|||||
Db 4845 AATGCACATCATGTGCGACCTGCTGCGCAATGAGGAGCATGTACCCAGGTACA 4786
Qy 787 tccatgaactgcgcagcagcttgaactaigtgttcaagctttaaagttgtgttt 846
|||||
Db 4785 TCACATGAACCTGGCGACGAGTTGACTTATGCTGTTTACGCTTTAAGSTGTGTGTTT 4726
Qy 847 ttgttttgcattatgttgcctgtaat 873
|||||
Db 4725 TTGTTTTCATTATGTGCTGTGTAAT 4699
RESULT 7
ABA08022/c
ID ABA08022 standard; DNA; 5469 BP.
XX
AC ABA08022;
XX
DT 11-JAN-2002 (first entry)
XX
DE Human ovarian and breast cancer associated polynucleotide SEQ ID NO 817.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
antiallergic; hepatotropic; antidiabetic; antiinflammatory; antileuc;
vulnerary; anticonvulsant; antibacterial; antitumoral; antiparasitic;
KW cardiacant; gene therapy; cancer; immune disorder; cardiovascular disorder;
neurological disease; infection; human; secreted protein; ds.
XX
KW Homo sapiens.
XX
PN WO20015325-A2.
PD
XX 02-AUG-2001.
PF 17-JAN-2001; 2001WO-US01345.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.

PR 22-AUG-2000; 2000US-0226686.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0228287.
PR 01-SEP-2000; 2000US-0228343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0233397.
PR 14-SEP-2000; 2000US-0233397.
PR 14-SEP-2000; 2000US-0233399.
PR 14-SEP-2000; 2000US-0233400.
PR 14-SEP-2000; 2000US-0233401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234423.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-02393935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.

XX	17-NOV-2000;	2000US-0249308.
PR	17-NOV-2000;	2000US-0249209.
PR	17-NOV-2000;	2000US-0249210.
PR	17-NOV-2000;	2000US-0249211.
PR	17-NOV-2000;	2000US-0249212.
PR	17-NOV-2000;	2000US-0249213.
PR	17-NOV-2000;	2000US-0249214.
PR	17-NOV-2000;	2000US-0249215.
PR	17-NOV-2000;	2000US-0249216.
PR	17-NOV-2000;	2000US-0249217.
PR	17-NOV-2000;	2000US-0249218.
PR	17-NOV-2000;	2000US-0249219.
PR	17-NOV-2000;	2000US-0249200.
PR	01-DEC-2000;	2000US-0250160.
PR	01-DEC-2000;	2000US-0250391.
PR	05-DEC-2000;	2000US-0251038.
PR	05-DEC-2000;	2000US-0251980.
PR	05-DEC-2000;	2000US-0256719.
PR	06-DEC-2000;	2000US-0251479.
PR	08-DEC-2000;	2000US-0251856.
PR	08-DEC-2000;	2000US-0251868.
PR	08-DEC-2000;	2000US-0251869.
PR	08-DEC-2000;	2000US-0251989.
PR	08-DEC-2000;	2000US-0251990.
PR	11-DEC-2000;	2000US-0254097.
PR	05-JAN-2001;	2001US-0259678.
PA	(HUMA-)	HUMAN GENOME SCI INC.
XX		
XX	Rosen CA, Barash SC, Ruben SM;	
PI		
XX	WPI: 2001-488786/53.	
DR		
XX		
PT	New isolated ovarian and/or breast cancer related nucleic acids and	
PT	polypeptides, useful for diagnosing, treating and/or preventing human	
PT	diseases and disorders, particularly ovarian and/or breast cancer -	
XX		
PS	Disclosure; SEQ ID NO 817; 577bp + Sequence Listing; English.	
XX		
CC	The invention relates to novel genes (ABA07454-ABA08224) and proteins	
CC	(ABA0743-ABA10980) useful for preventing, treating or ameliorating	
CC	medical conditions e.g. by protein or gene therapy. The genes are	
CC	isolated from a range of human tissues disclosed in the specification.	
CC	The nucleic acids, proteins, antibodies and (ant)agonists are useful	
CC	in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast	
CC	and ovarian cancer and other cancers of the adrenal gland, bone, bone	
CC	marrow, breast, gastrointestinal tract, liver, lung, or urogenital;	
CC	(b) immune disorders e.g. Addison's disease, allergies, autoimmune	
CC	hemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's	
CC	colitis; (c) cardiovascular disorders such as myocardial ischaemias;	
CC	(d) wound healing; (e) neurological diseases e.g. cerebral anoxia; and	
CC	epilepsy; and (f) infectious diseases such as viral, bacterial, fungal	
CC	and parasitic infections.	
CC	Note: The sequence data for this patent did not form part of the	
CC	printed specification, but was obtained in electronic format directly	
CC	from WIPO at ftp.wipo.int/pub/published_pctl_sequences .	
XX		
XX	Sequence 5469 BP; 1793 A; 1119 C; 1201 G; 1356 T; 0 other;	

Query Match	30.48	Score 265.4	DB 22	Length 5469
Best Local Similarity	99.68	Pred. No. 6.5e-63		
Matches 266	Conservative	0	Mismatches 1	Indels 0
				Gaps 0

QY 607 agagggcaaaagaaggaaaaagcagagcgcttggatgtgcctgtaglaaagtccfga 666
+ | ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 4965 ACACGCCAAGAGAGCGAAAGAGCAGAGCCGTTTGGATTCGCTGATGANAAGTTCTGA 4306

OY	667	tactctcttgcttccagtgcttttccattctctctctctctcttggtcaacataatgcta	726
Db	4905	TACTTTCTGTTCTCCAGTGTTTTCCATTTCTCTCTCTCTCTTCTTGCGACATATATGCGCTA	4846
OY	727	aatgcacagatcatgtgctctacgcctccgcctcgaatgaagagagcatgtaacccagatgaca	786
Db	4845	AATGCACAGTCATATGTGCTCTACGCTCTGCTCTCGCAATGAGGAGCATATATCCCAAGTACA	4786
OY	787	lccatlgacttcgagcagcagtttgacttaattgcttgcttcaagctttaaagtttgctt	846
Db	4785	TCCATGAAACGCGGCGACACAGTTTGACATATATGCTGTTTCAGCTTAAAGTTTGTGTGTT	4726
OY	847	ttgcttttgatataatgcttgcttgaat	873
Db	4725	TTGTTTTGATTATGTTGCTTTGAAT	699

RESULT	8
AAL06683/c	
ID	AAL06683 standard; DNA; 5469 BP.

AC AAL06683

DT 21-NOV-2001 (first entry)

DE Human reproductive system related antigen DNA SEQ ID NO: 9371.

KW Human; reproductive system related antigen; reproductive system disorder,
KW cancer; gene therapy; ds.

OS Homo sapiens

PN W0200155320-A2

PD 02-AUG-2001

17-JAN-2001; 2001WO-US013339.

31-JAN-2000; 2000US-0179065.

PR 24-FEB-2000: 2000US-0184664

PR 16-MAR-2000: 2000US-0189874

PR 18-MAR-2000; 2000US-0190076.
PR 18-MAR-2000; 2000US-0198123

PR 19-MAY-2000; 2000US-0205515; 07 JUN 2000; 2000US-0200457

PR 28-JUN-2000; 2000US-0214886.

PR 07-JUL-2000; 2000US-0216647.

PR 11-JUL-2000; 2000US-0217487.

PR 14-JUL-2000; 2000US-0218290.

PR 26-JUL-2000; 2000US-0220964.

PR 14-AUG-2000; 2000US-0224519.

PR 14-AUG-2000; 2000US-0225214.

14-AUG-2000; 2000US-0225267.

PR 14-AUG-2000; 2000US-0225270.

PR 14-AUG-2000: 2000US-0225757

PR 14-AUG-2000: 2000HS-0225759

PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0236681

PR 22-AUG-2000; 2000US-0226868;
PR 22-AUG-2000; 2000US-0327183

RESULT 9
AAK84119/c
ID AAK84119 standard; DNA, 5469 BP.
XX
XX AAK84119;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:38931.
XX
XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytosolic; gene therapy; vaccine; metastasis; ds.
XX
XX Homo sapiens.
OS
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01354.
PF
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225256.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 23-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.

PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237040.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.

Db 8709 TTGTTTTCATTATGTCCTGCTTAAT 8683

RESULT 11
ABA08021/C
ID ABA08021 standard; DNA; 9453 BP.
XX
AC ABA08021;
XX
XX 11-JAN-2002 (first entry)
XX
DE Human ovarian and breast cancer associated polynucleotide SEQ ID NO 816.
XX
XX Cytostatic; immunosuppressive; noctropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antinflammatory; antiulcer;
KW vulnerrary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein; ds.
XX
OS Homo sapiens.
XX
PN WO200155325-A2.
XX
PD 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01345.
PF
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0244674.
PR 08-NOV-2000; 2000US-0244675.
PR 08-NOV-2000; 2000US-0244676.
PR 08-NOV-2000; 2000US-0244677.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.


```

PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 25-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0244674.
PR 08-NOV-2000; 2000US-0244675.
PR 08-NOV-2000; 2000US-0244676.
PR 08-NOV-2000; 2000US-0244677.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.

```

```

PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0251988.
PR 06-DEC-2000; 2000US-0251988.
PR 06-DEC-2000; 2000US-0251988.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251859.
PR 08-DEC-2000; 2000US-0251859.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI, 2001-465570/50.
XX
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
XX
PS Disclosure; SEQ ID NO 9370; 1297pp + Sequence Listing; English.
XX
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 9453 BP; 2869 A; 2071 C; 2294 G; 2219 T; 0 other;

```

```

Query Match 30.4%; Score 265.4; DB 22; Length 9453;
Best Local Similarity 99.6%; Pred. No. 8.4e-63;
Matches 266; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 607 agaggcaagaagaggaagagagagagcgttggtgattgctgtaagaaagttccgta 666
DB 8949 ACAGCGAAAGAGAGAGAGAGAGAGAGCGCTTTGGATTGCTGATGAAAGTTCCCTGA 8890
QY 667 taattctgtctcagtggttttccattctctccttcttcttggttccataatgctta 726
DB 8889 TACTTTCGTCTCCAGCTTTTCCATTCTCTCTCTCTCTGTCACATATATGCCCTA 8830
QY 727 aatgcacagtcacatgctcctcctgcctgcgaatgagagagacatgtaaccaggtaca 786
DB 8829 AATGCACAGTCATGTCCTACCTCCGCTCCCAATGAGGAGCATGTACCCAGGTACA 8770
QY 787 tccatgaactggcgcagcagcgtttgactatgcttgcgttgaagtttgaagtttgctt 846
DB 8769 TCCATGAAGTGGCGCAGCAGTGTGACTTATGCTGTTGACCTTGAAGTGTGTGTTT 8710
QY 847 tctgtttgatatgcttgcttgaat 873
DB 8709 TGTGTTTGATTATGTTGCTGTGTAAT 8683

```

```

RESULT 13
AAK84118/c
ID AAK84118 standard; DNA; 9453 BP.
XX
AC AAK84118;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:38930.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.

```


XX Homo sapiens.
OS
XX WO200157182-A2.
PN
XX 09-AUG-2001.
PD
XX 17-JAN-2001; 2001WO-US01354.
PE
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.

PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236357.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246539.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246539.
PR 08-NOV-2000; 2000US-0246602.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249246.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 06-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0251990.
PR 05-JAN-2001; 2001US-0259678.
XX

THIS PAGE BLANK (USPTO)